Annovis Bio to Present at the Online Spring Investor Summit on March 25

NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, is scheduled to present at the Spring Investor Summit on March 25 at 3:30 p.m. EST.

Due to ongoing concerns from COVID-19, The Spring Investor Summit, which was originally scheduled to take place in New York City, will now be hosted virtually.

Investors will be able to view Annovis Bio’s presentation directly on the conference event platform on March 25 at 3:30 p.m. EST. One-on-one meetings will now be scheduled and conducted via phone lines with a dedicated PIN for each meeting.

To view the Annovis Bio webcast, visit https://www.webcaster4.com/Webcast/Page/2038/33641 on March 25, 2020 at 3.30 p.m. EST.

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and plan to commence a second Phase 2a study in PD patients. For more information on Annovis, please visit the company’s website: www.annovisbio.com.

About Spring Investor Summit

The Spring Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting small-cap and microcap companies with qualified investors.

To register as a presenting company: please contact Cassandra Miller (cassandra@microcapconf.com)

To request complimentary investor registration: please visit our website at www.microcapconf.com

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Cassandra Miller at cassandra@microcapconf.com

Investor Relations:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

SOURCE: Annovis Bio

View source version on accesswire.com:
https://www.accesswire.com/581467/Annovis-Bio-to-Present-at-the-Online-Spring-Investor-Summit-on-March-25

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

13 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

13 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

2 days ago